Eva
Fernández Rodríguez
Instituto de Salud Carlos III
Madrid, EspañaPublicaciones en colaboración con investigadores/as de Instituto de Salud Carlos III (10)
2021
-
Molecular determinants of enhanced response to somatostatin receptor ligands after debulking in large GH-producing adenomas
Clinical Endocrinology, Vol. 94, Núm. 5, pp. 811-819
2015
-
Hypopituitarism After Traumatic Brain Injury
Endocrinology and Metabolism Clinics of North America, Vol. 44, Núm. 1, pp. 151-159
-
Influence of the exon 3 deletion of GH receptor and IGF-I level at diagnosis on the efficacy and safety of treatment with somatotropin in adults with GH deficiency
Pituitary, Vol. 18, Núm. 1, pp. 101-107
-
Update on prognostic factors in acromegaly: Is a risk score possible?
Pituitary, Vol. 18, Núm. 3, pp. 431-440
2013
-
Epidemiology, mortality rate and survival in a homogeneous population of hypopituitary patients
Clinical Endocrinology, Vol. 78, Núm. 2, pp. 278-284
2012
-
Subclinical hypopituitarism
Best Practice and Research: Clinical Endocrinology and Metabolism, Vol. 26, Núm. 4, pp. 461-469
2011
-
Pituitary stalk dysgenesis-induced hypopituitarism in adult patients: Prevalence, evolution of hormone dysfunction and genetic analysis
Neuroendocrinology, Vol. 93, Núm. 3, pp. 181-188
2010
-
Hypopituitarism following traumatic brain injury: Determining factors for diagnosis
Frontiers in Endocrinology, Vol. 2, Núm. AUG
-
Pegvisomant-induced liver injury is related to the UGT1A1*28 polymorphism of Gilbert's syndrome
Journal of Clinical Endocrinology and Metabolism, Vol. 95, Núm. 5, pp. 2147-2154
-
The exon 3-deleted growth hormone receptor is associated with better response to pegvisomant therapy in acromegaly
Journal of Clinical Endocrinology and Metabolism, Vol. 95, Núm. 1, pp. 222-229